Pharma BD Deal Intelligence
A $118B unsolicited bid that would have been pharma's largest-ever deal—AstraZeneca's board rejected it outright, and UK takeover rules boxed Pfizer out for six months. Pfizer withdrew empty-handed, leaving the oncology pipeline it coveted entirely in AstraZeneca's hands.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Pfizer increases offer for AstraZeneca to approximately $118 billion. AstraZeneca board ultimately rejects the final proposal stating Pfizer has failed to make…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Pfizer made an unsolicited bid to acquire AstraZeneca for approximately $118 billion, which would have been the largest pharmaceutical deal in history. AstraZeneca's board rejected the bid, and Pfizer ultimately withdrew after UK takeover rules prevented a further approach for six months.
Tagrisso (osimertinib) is the standard-of-care third-generation EGFR TKI in EGFR-mutant NSCLC, competing across EGFR TKI generations, amivantamab-based regimens, and combination strategies. Third-generation EGFR TKIs (direct MOA): lazertinib (Leclaza, Yuhan/J&J) is FDA-approved in combination with amivantamab in first-line EGFR-mutant NSCLC per MARIPOSA; aumolertinib (Ameile, Hansoh) is approved in China. First- and second-generation EGFR TKIs: erlotinib (Tarceva, Astellas/Roche), gefitinib (Iressa, AstraZeneca), afatinib (Gilotrif, Boehringer), and dacomitinib (Vizimpro, Pfizer) are FDA-approved but superseded by osimertinib in first-line per FLAURA. EGFR/MET bispecific antibodies: amivantamab (Rybrevant, J&J) is FDA-approved as monotherapy in EGFR exon 20 insertion NSCLC and in combinations for EGFR exon 19/L858R disease. EGFR exon 20 insertion TKIs: mobocertinib (Exkivity, Takeda, voluntarily withdrawn 2023). Chemotherapy-combination strategies: osimertinib plus pemetrexed/platinum (FLAURA2) and amivantamab plus lazertinib (MARIPOSA) reset the first-line standard. HER3 ADC: patritumab deruxtecan (HER3-DXd, Daiichi Sankyo/Merck) is in late-stage EGFR-mutant NSCLC trials post-TKI progression. Per AstraZeneca's FY 2023 Annual Report, Tagrisso recorded $5.8B in revenue; for a commercial lead, the principal threat is MARIPOSA-regimen uptake in first-line and emerging ADCs in resistance.
Nexium (esomeprazole) competes in GERD, erosive esophagitis, and H. pylori eradication across acid-suppression MOA classes. Proton pump inhibitors (direct MOA competitors): omeprazole (Prilosec, AstraZeneca), lansoprazole (Prevacid, Takeda), pantoprazole (Protonix, Pfizer), rabeprazole (Aciphex, Eisai/Janssen), and dexlansoprazole (Dexilant, Takeda) are FDA-approved; all except Dexilant are available as generics and OTC formulations (omeprazole, esomeprazole, lansoprazole) erode branded share materially. Potassium-competitive acid blockers (P-CABs): vonoprazan (Voquezna, Phathom) is FDA-approved for erosive esophagitis, non-erosive GERD, and H. pylori eradication triple/dual therapy, positioned as a next-generation acid suppressor with faster onset and sustained pH control. H2-receptor antagonists: famotidine (Pepcid, J&J/OTC), cimetidine (Tagamet), and nizatidine (Axid) are generic and OTC, used for milder disease or nocturnal breakthrough symptoms; ranitidine (Zantac) was withdrawn in 2020 following NDMA contamination findings. Antacids and alginate/antacid combinations (Gaviscon, Reckitt) are broadly OTC and serve mild/intermittent GERD. Mucosal protectants: sucralfate (Carafate) is used in select esophagitis/ulcer populations. For a commercial lead, Nexium lost US exclusivity in 2014 and faces sustained generic and OTC pressure; vonoprazan is the most meaningful branded threat in refractory GERD.
Onglyza (saxagliptin) competes in Type 2 diabetes across oral and injectable antihyperglycemic classes, with the DPP-4 class facing structural displacement by GLP-1s and SGLT2s in guidelines. DPP-4 inhibitors (direct MOA competitors): sitagliptin (Januvia, Merck), linagliptin (Tradjenta, Boehringer/Lilly), alogliptin (Nesina, Takeda), and vildagliptin (Galvus, Novartis, ex-US) are FDA- or EMA-approved; sitagliptin historically led the class on volume share. GLP-1 receptor agonists: semaglutide (Ozempic, Rybelsus, Novo Nordisk), liraglutide (Victoza, Novo), dulaglutide (Trulicity, Lilly), exenatide (Bydureon, AstraZeneca), and tirzepatide (Mounjaro, dual GIP/GLP-1, Lilly) dominate share gains with CV and renal outcomes labels. SGLT2 inhibitors: empagliflozin (Jardiance, Boehringer/Lilly), dapagliflozin (Farxiga, AstraZeneca), canagliflozin (Invokana, Janssen), and ertugliflozin (Steglatro, Merck) are FDA-approved with CV, HF, and CKD outcomes data. Biguanides: metformin remains universal first-line per ADA Standards of Care. Sulfonylureas and thiazolidinediones (glimepiride, pioglitazone) persist as low-cost generics. For a commercial lead, the DPP-4 class saw the saxagliptin SAVOR-TIMI 53 heart-failure signal narrow label positioning; post-2019 ADA/EASD consensus prioritizing GLP-1/SGLT2 in patients with ASCVD, HF, or CKD has compressed Onglyza's franchise trajectory.
Crestor (rosuvastatin) anchors AstraZeneca's dyslipidemia franchise and competes in LDL-C lowering across multiple MOA classes. HMG-CoA reductase inhibitors (statins): atorvastatin (Lipitor, Pfizer), simvastatin (Zocor, Merck), pravastatin (Pravachol, BMS), lovastatin (Mevacor, Merck), pitavastatin (Livalo, Kowa), and fluvastatin (Lescol, Novartis) are all FDA-approved; atorvastatin and rosuvastatin are the highest-potency agents and dominant by prescription volume, with atorvastatin generic since 2011 and rosuvastatin generic since 2016. Cholesterol absorption inhibitors: ezetimibe (Zetia, Merck) is approved as monotherapy and in fixed-dose with simvastatin (Vytorin) and rosuvastatin (Roszet); ezetimibe added to statin reduced MACE in IMPROVE-IT. PCSK9 monoclonal antibodies: evolocumab (Repatha, Amgen) and alirocumab (Praluent, Regeneron/Sanofi) deliver 50-60 percent additional LDL-C reduction on top of statin, FDA-approved with CV outcomes labels. PCSK9 siRNA: inclisiran (Leqvio, Novartis) is FDA-approved for primary hypercholesterolemia with twice-yearly dosing. ATP-citrate lyase inhibitor: bempedoic acid (Nexletol, Esperion) is FDA-approved with a CV outcomes label from CLEAR. Crestor lost US exclusivity in 2016; for a commercial lead, the threat today is generic rosuvastatin price erosion and PCSK9-class uptake in secondary prevention.
Symbicort (budesonide/formoterol) competes across ICS/LABA maintenance, triple therapy, and biologic MOA classes in asthma and COPD. ICS/LABA combinations (direct MOA competitors): fluticasone furoate/vilanterol (Breo Ellipta, GSK), fluticasone propionate/salmeterol (Advair Diskus, Airduo, GSK; multiple generics including Wixela), mometasone/formoterol (Dulera, Organon), and fluticasone/salmeterol generics are FDA-approved and dominate the maintenance market. ICS/LABA/LAMA triple therapies: fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta, GSK) and budesonide/glycopyrrolate/formoterol (Breztri Aerosphere, AstraZeneca) are FDA-approved in COPD; Trelegy is also approved in asthma. LAMA/LABA combinations: umeclidinium/vilanterol (Anoro Ellipta, GSK), tiotropium/olodaterol (Stiolto Respimat, Boehringer), glycopyrrolate/formoterol (Bevespi Aerosphere, AstraZeneca), and indacaterol/glycopyrrolate (Utibron Neohaler, Novartis/Sunovion) are FDA-approved in COPD. Biologics (asthma): omalizumab (Xolair, Genentech/Novartis, anti-IgE), mepolizumab (Nucala, GSK, anti-IL-5), benralizumab (Fasenra, AstraZeneca, anti-IL-5Ralpha), reslizumab (Cinqair, Teva, anti-IL-5), dupilumab (Dupixent, Regeneron/Sanofi, anti-IL-4Ralpha), and tezepelumab (Tezspire, AstraZeneca/Amgen, anti-TSLP) are FDA-approved for severe asthma phenotypes. Per AstraZeneca's FY 2023 Annual Report, Symbicort revenue was approximately $2.2B. For a commercial lead, generic Advair and Wixela erosion, plus Trelegy/Breztri triple-therapy uptake in COPD, are the principal franchise threats.
Pfizer made an unsolicited bid to acquire AstraZeneca for approximately $118 billion, which would have been the largest pharmaceutical deal in history. AstraZeneca's board rejected the bid, and Pfizer ultimately withdrew after UK takeover rules prevented a further approach for si
Deal terminated after AstraZeneca PLC rejected the acquisition proposal from Pfizer Inc..
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / AstraZeneca PLC (this deal) | 2014 | $118.0B | 27 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2014 deals · Pfizer Inc. deals · Cardiovascular deals